Cumulative live birth rate of in vitro fertilization cycle via progestin-primed ovarian stimulation versus gonadotropin-releasing hormone antagonist protocol in infertile women with normal ovarian reserve: an open-label, randomized controlled trial

References

• Allegra, A., Marino, A., Coffaro, F., Scaglione, P., Sammartano, F., Rizza, G., & Volpes, A. (2007). GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial. Human Reproduction, 22(1), 101–108. https://doi.org/10.1093/humrep/del337
   PubMed Web of Science ®Google Scholar
• Beguería, R., García, D., Vassena, R., & Rodríguez, A. (2019). Medroxyprogesterone acetate versus ganirelix in oocyte donation: A randomized controlled trial. Human Reproduction, 34(5), 872–880. https://doi.org/10.1093/humrep/dez034
   PubMed Web of Science ®Google Scholar
• Chen, H., Teng, X. M., Sun, Z. L., Yao, D., Wang, Z., & Chen, Z. Q. (2022). Comparison of the cumulative live birth rates after 1 in vitro fertilization cycle in women using gonadotropin-releasing hormone antagonist protocol vs. progestin-primed ovarian stimulation: A propensity score-matched study. Fertility and Sterility, 118(4), 701–712. https://doi.org/10.1016/j.fertnstert.2022.06.012
   PubMed Web of Science ®Google Scholar
• Chen, Q., Chai, W., Wang, Y., Cai, R., Zhang, S., Lu, X., Zeng, X., Sun, L., & Kuang, Y. (2019). Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: A randomized controlled trial. Frontiers in Endocrinology, 10, 796. https://doi.org/10.3389/fendo.2019.00796
   PubMed Web of Science ®Google Scholar
• Chen, Q., Wang, Y., Sun, L., Zhang, S., Chai, W., Hong, Q., Long, H., Wang, L., Lyu, Q., & Kuang, Y. (2017). Controlled ovulation of the dominant follicle using progestin in minimal stimulation in poor responders. Reproductive Biology and Endocrinology, 15(1), 71. https://doi.org/10.1186/s12958-017-0291-0
   PubMedGoogle Scholar
• Copperman, A. B., & Benadiva, C. (2013). Optimal usage of the GnRH antagonists: A review of the literature. Reproductive Biology and Endocrinology, 11(1), 20. https://doi.org/10.1186/1477-7827-11-20
   PubMedGoogle Scholar
• Dong, J., Wang, Y., Chai, W. R., Hong, Q. Q., Wang, N. L., Sun, L. H., Long, H., Wang, L., Tian, H., Lyu, Q. F., Lu, X. F., Chen, Q. J., & Kuang, Y. P. (2017). The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: A randomised controlled trial. BJOG: An International Journal of Obstetrics and Gynaecology, 124(7), 1048–1055. https://doi.org/10.1111/1471-0528.14622
   PubMed Web of Science ®Google Scholar
• Du, M., Zhang, J., Li, Z., Liu, X., Li, J., Liu, W., & Guan, Y. (2021). Comparison of the cumulative live birth rates of progestin-primed ovarian stimulation and flexible GnRH antagonist protocols in patients with low prognosis. Frontiers in Endocrinology, 12, 705264. https://doi.org/10.3389/fendo.2021.705264
   PubMed Web of Science ®Google Scholar
• Duijkers, I. J., Klipping, C., Willemsen, W. N., Krone, D., Schneider, E., Niebch, G., & Hermann, R. (1998). Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Human Reproduction, 13(9), 2392–2398. https://doi.org/10.1093/humrep/13.9.2392
   PubMed Web of Science ®Google Scholar
• Giles, J., Alama, P., Gamiz, P., Vidal, C., Badia, P., Pellicer, A., & Bosch, E. (2021). Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: A randomized, controlled trial. Fertility and Sterility, 116(2), 404–412. https://doi.org/10.1016/j.fertnstert.2021.02.036
   PubMed Web of Science ®Google Scholar
• Guan, S., Feng, Y., Huang, Y., & Huang, J. (2021). Progestin-primed ovarian stimulation protocol for patients in assisted reproductive technology: A meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 12, 702558. https://doi.org/10.3389/fendo.2021.702558
   PubMed Web of Science ®Google Scholar
• He, W., Li, X., Adekunbi, D., Liu, Y., Long, H., Wang, L., Lyu, Q., Kuang, Y., & O’Byrne, K. T. (2017). Hypothalamic effects of progesterone on regulation of the pulsatile and surge release of luteinising hormone in female rats. Scientific Reports, 7(1), 8096. https://doi.org/10.1038/s41598-017-08805-1
   PubMedGoogle Scholar
• Kalafat, E., Turkgeldi, E., Yıldız, S., Dizdar, M., Keles, I., & Ata, B. (2022). Outcomes of a GnRH agonist trigger following a GnRH antagonist or flexible progestin-primed ovarian stimulation cycle. Frontiers in Endocrinology, 13, 837880. https://doi.org/10.3389/fendo.2022.837880
   PubMed Web of Science ®Google Scholar
• Kuang, Y., Chen, Q., Fu, Y., Wang, Y., Hong, Q., Lyu, Q., Ai, A., & Shoham, Z. (2015). Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertility and Sterility, 104(1), 62.e3–70.e3. https://doi.org/10.1016/j.fertnstert.2015.03.022
   PubMed Web of Science ®Google Scholar
• La Marca, A., & Capuzzo, M. (2019). Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: The beginning of a new era? Reproductive Biomedicine Online, 39(2), 321–331. https://doi.org/10.1016/j.rbmo.2019.03.212
   PubMed Web of Science ®Google Scholar
• Lin, Y., Chen, Q., Zhu, J., Teng, Y., Huang, X., & Chen, X. (2021). Progestin-primed ovarian stimulation with clomiphene citrate supplementation may be more feasible for young women with diminished ovarian reserve compared with standard progestin-primed ovarian stimulation: A retrospective study. Drug Design, Development and Therapy, 15, 5087–5097. https://doi.org/10.2147/DDDT.S338748
   PubMed Web of Science ®Google Scholar
• Liu, Y., Li, X., Ivanova, D., Lass, G., He, W., Chen, Q., Yu, S., Wang, Y., Long, H., Wang, L., Lyu, Q., Kuang, Y., & O’Byrne, K. T. (2020). Dynorphin and GABAA receptor signaling contribute to progesterone’s inhibition of the LH surge in female mice. Endocrinology, 161(5), 442–452. https://doi.org/10.1210/endocr/bqaa036
   Web of Science ®Google Scholar
• Lu, X., Khor, S., Zhu, Q., Sun, L., Wang, Y., Chen, Q., Wu, L., Fu, Y., Tian, H., Lyu, Q., Cai, R., & Kuang, Y. (2018). Decrease in preovulatory serum estradiol is a valuable marker for predicting premature ovulation in natural/unstimulated in vitro fertilization cycle. Journal of Ovarian Research, 11(1), 96. https://doi.org/10.1186/s13048-018-0469-x
   PubMedGoogle Scholar
• Luo, Y., Liu, S., Su, H., Hua, L., Ren, H., Liu, M., Wan, Y., Li, H., & Li, Y. (2021). Low serum LH levels during ovarian stimulation with GnRH antagonist protocol decrease the live birth rate after fresh embryo transfers but have no impact in freeze-all cycles. Frontiers in Endocrinology, 12, 640047. https://doi.org/10.3389/fendo.2021.640047
   PubMed Web of Science ®Google Scholar
• Massin, N. (2017). New stimulation regimens: Endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Human Reproduction Update, 23(2), 211–220. https://doi.org/10.1093/humupd/dmw047
   PubMed Web of Science ®Google Scholar
• Namavar Jahromi, B., Parsanezhad, M. E., Shomali, Z., Bakhshai, P., Alborzi, M., Moin Vaziri, N., & Anvar, Z. (2018). Ovarian hyperstimulation syndrome: A narrative review of its pathophysiology, risk factors, prevention, classification, and management. Iranian Journal of Medical Sciences, 43(3), 248–260. https://doi.org/10.30476/ijms.2018.40535
   PubMed Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. (2016). Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: A guideline. Fertility and Sterility, 106(7), 1634–1647. https://doi.org/10.1016/j.fertnstert.2016.08.048
   PubMed Web of Science ®Google Scholar
• Rabinovici, J., Rothman, P., Monroe, S. E., Nerenberg, C., & Jaffe, R. B. (1992). Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: Studies in postmenopausal women. The Journal of Clinical Endocrinology and Metabolism, 75(5), 1220–1225. https://doi.org/10.1210/jcem.75.5.1385467
   PubMed Web of Science ®Google Scholar
• Shen, X., Long, H., Guo, W., Xie, Y., Gao, H., Zhang, J., Wang, Y., Lyu, Q., Kuang, Y., & Wang, L. (2020). The ovulation trigger-OPU time interval of different ovarian protocols in ART: A retrospective study. Archives of Gynecology and Obstetrics, 302(2), 519–527. https://doi.org/10.1007/s00404-020-05568-5
   PubMed Web of Science ®Google Scholar
• Toftager, M., Bogstad, J., Løssl, K., Prætorius, L., Zedeler, A., Bryndorf, T., Nilas, L., & Pinborg, A. (2017). Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: Secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols. Human Reproduction, 32(3), 556–567. https://doi.org/10.1093/humrep/dew358
   PubMed Web of Science ®Google Scholar
• Wang, Y., Chen, Q., Wang, N., Chen, H., Lyu, Q., & Kuang, Y. (2016). Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: A double-blind randomized crossover clinical trial. Medicine, 95(9), e2939. https://doi.org/10.1097/md.0000000000002939
   PubMed Web of Science ®Google Scholar
• Wang, Y., Kuang, Y., Chen, Q., & Cai, R. (2018). Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: Study protocol for a randomised controlled trial. Trials, 19(1), 455. https://doi.org/10.1186/s13063-018-2850-x
   PubMedGoogle Scholar
• Wei, D., Liu, J.-Y., Sun, Y., Shi, Y., Zhang, B., Liu, J.-Q., Tan, J., Liang, X., Cao, Y., Wang, Z., Qin, Y., Zhao, H., Zhou, Y., Ren, H., Hao, G., Ling, X., Zhao, J., Zhang, Y., Qi, X., … Chen, Z.-J. (2019). Frozen versus fresh single blastocyst transfer in ovulatory women: A multicentre, randomised controlled trial. Lancet, 393(10178), 1310–1318. https://doi.org/10.1016/S0140-6736(18)32843-5
   PubMed Web of Science ®Google Scholar
• Xiao, Z. N., Peng, J. L., Yang, J., & Xu, W. M. (2019). Flexible GnRH antagonist protocol versus progestin-primed ovarian stimulation (PPOS) protocol in patients with polycystic ovary syndrome: Comparison of clinical outcomes and ovarian response. Current Medical Science, 39(3), 431–436. https://doi.org/10.1007/s11596-019-2055-x
   PubMed Web of Science ®Google Scholar
• Yildiz, S., Turkgeldi, E., Angun, B., Eraslan, A., Urman, B., & Ata, B. (2019). Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology. Fertility and Sterility, 112(4), 677–683. https://doi.org/10.1016/j.fertnstert.2019.06.009
   PubMed Web of Science ®Google Scholar
• Yu, C. M., Dai, X. L., Wang, Y. F., Gao, T. T., Cao, F., Xia, X. Y., & Chen, L. (2019). Progestin-primed ovarian stimulation improves the outcomes of IVF/ICSI cycles in infertile women with diminished ovarian reserve. Journal of the Chinese Medical Association: JCMA, 82(11), 845–848. https://doi.org/10.1097/JCMA.0000000000000177
   PubMed Web of Science ®Google Scholar
• Zacà, C., Bazzocchi, A., Pennetta, F., Bonu, M. A., Coticchio, G., & Borini, A. (2018). Cumulative live birth rate in freeze-all cycles is comparable to that of a conventional embryo transfer policy at the cleavage stage but superior at the blastocyst stage. Fertility and Sterility, 110(4), 703–709. https://doi.org/10.1016/j.fertnstert.2018.05.012
   PubMed Web of Science ®Google Scholar
• Zegers-Hochschild, F., Adamson, G. D., Dyer, S., Racowsky, C., de Mouzon, J., Sokol, R., Rienzi, L., Sunde, A., Schmidt, L., Cooke, I. D., Simpson, J. L., & van der Poel, S. (2017). The International glossary on infertility and fertility care, 2017. Human Reproduction, 32(9), 1786–1801. https://doi.org/10.1093/humrep/dex234
   PubMed Web of Science ®Google Scholar
• Zhang, S., Yin, Y., Li, Q., & Zhang, C. (2021). Comparison of cumulative live birth rates between GnRH-A and PPOS in low-prognosis patients according to POSEIDON criteria: A cohort study. Frontiers in Endocrinology, 12, 644456. https://doi.org/10.3389/fendo.2021.644456
   PubMed Web of Science ®Google Scholar
• Zhu, X., Ye, H., Ye, J., & Fu, Y. (2021). Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: A prospective randomized controlled trial. Annals of Translational Medicine, 9(5), 387–387. https://doi.org/10.21037/atm-20-1592
   PubMed Web of Science ®Google Scholar
• Zimmerman, L., Willson, S., Setton, R., & Schattman, G. (2022). Ovarian stimulation for fertility preservation (different protocols). In M. Grynberg & P. Patrizio (Eds.), Female and male fertility preservation (pp. 119–129). Springer. https://doi.org/10.1007/978-3-030-47767-7_9
   Google Scholar